Open access · US-GOV
via ClinicalTrials.gov Clinical trial
The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity
Authors not listed
Sara Espinoza · 2017
Abstract
Obesity is highly prevalent in older adults and is a major cause of sarcopenia and disability in older adults. Although exercise can counteract the effects of obesity and sarcopenia, many have difficulty adhering to an exercise program and the benefits of exercise are variable. Therefore, there is an urgent need to test novel pharmacologic interventions to prevent disability and loss of independence. Oxytocin is a pituitary hormone released during parturition and lactation that is also known to suppress appetite in rodents and humans; and, recent small studies have found that intranasal oxytocin reduces body weight in adults. We propose a pilot study of intranasal oxytocin as a novel approach to promote weight loss and increase muscle mass in older subjects with sarcopenic obesity.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-07-02 MST
Cite this
APA
Anonymous. (2017). The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity. <em>Sara Espinoza</em>. https://clinicaltrials.gov/study/NCT03119610
Vancouver
Anonymous. The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity. Sara Espinoza. 2017.
BibTeX
@misc{anon2017ThePhy,
title = {The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity},
author = {Anonymous},
journal = {Sara Espinoza},
year = {2017},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.